Creative Medical Technology Holdings, Inc. (CELZ) is a biotechnology company developing regenerative medicine and immunotherapy technologies intended to improve patient health. Its work spans immunology, endocrinology, urogynecology, and orthopedics, supported by a scientific and medical team, a defined development strategy, and a portfolio of more than 60 pending or issued patents.

The company advances several platforms, including Supercharged Autologous Immunotherapy and Rapid Autologous Stem Cell therapies. ImmCelz, its first autologous immunotherapy platform, uses factors secreted by universal donor cells to reprogram a patient’s own immune cells. AlloStem is an enhanced allogeneic cell platform using perinatal-derived tissue cells, while iPSCELZ is a developing cellular reprogramming platform with the potential to create different cell types from a patient’s cells. StemSpine, OvaStem, and CaverStem are programs based on the rapid autologous therapy platform.

Creative Medical Technology also conducts clinical development, including trials in type 1 diabetes and lower back pain, and collaborates with nonprofit and for-profit organizations on technology development.